The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Biomarker-driven Applications Of Immunotherapy In Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Immunotherapy is a new treatment strategy that works in many different lymphoma types but there is no successful method of predicting response or selecting patients. I aim to explore use of immunotherapy in 3 key lymphoma subtypes to identify new techniques for predicting which patients respond to treatment through prospective biomarker research using novel techniques. These aims will be achieved through a series of clinical trials of immunotherapy in lymphoma all with a biomarker research focus
Assessing The Utility Of Circulating Cell-free MicroRNA As Biomarkers For Response In A Variety Of Non Hodgkin Lymphomas
Funder
National Health and Medical Research Council
Funding Amount
$92,159.00
Summary
Non Hodgkin Lymphomas are the most common blood cancer to affect adult Australians. The current strategies for diagnosis, treatment and monitoring of these patients are generic and not tailored to features of particular patientÍs lymphoma or treatment response. We aim to develop a new blood based marker for Lymphoma that can be used to diagnose and monitor NHL patients, to allow treatment to be adjusted according the patients current response to therapy, as indicated by the blood based marker. T
Redirecting T-cells For Immunotherapy Of Leukaemia And Lymphoma By The Expression Of A CD19-specific Chimeric Antigen Receptor Using The PiggyBac Transposon Gene Modification System
Funder
National Health and Medical Research Council
Funding Amount
$374,876.00
Summary
Most lymphomas respond to therapy but then relapse. Immune cells can attack and kill virus related lymphomas. However, most lymphomas are NOT virus related. We will create immune cells targeting these virus negative lymphomas by inserting artificial receptors into the immune cells. These receptors attach to the lymphoma and activate the immune cells. The immune cells will home to the lymphoma, kill lymphoma cells and persist in the body for many years, preventing lymphoma relapse.
A Population-based Family Study Of Follicular Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$1,703,070.00
Summary
Annually more than 900 Australians are diagnosed with follicular lymphoma. The proposed research aims identify the environmental and genetic causes of this serious blood cancer. People diagnosed with lymphoma, and a family member, will provide detailed personal and family histories, and a blood sample. Exposure to specific chemicals, types of work, sun exposure, and body size are some of the factors the study will examine. The 5-year study will be conducted in NSW, ACT and Victoria.
The aim of my research is to investigate the role that physical activity and sedentary behaviour (too much sitting) play in the development of cancer. My research will increase our understanding of how physical activity and sedentary behaviour influence cancer, and may lead to new strategies for cancer prevention.
A Prospective Single Arm Trial Of Involved-field Radiotherapy For Stage I-II Low Grade Nongastric Marginal Zone Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$363,869.00
Summary
This is an international, multicentre study that will, for the first time, prospectively measure the curative potential of radiotherapy in localised marginal zone lymphoma (MZL). Most MZL arises in mucosa-associated lymphoid tissue (MALT), either in the stomach or in a range of other organs such as salivary glands, the tissues around the eye or the thyroid. Many stomach MALT lymphomas are caused by infection with Helicobacter Pylori. This infection can also be associated with non-gastric MALT ly ....This is an international, multicentre study that will, for the first time, prospectively measure the curative potential of radiotherapy in localised marginal zone lymphoma (MZL). Most MZL arises in mucosa-associated lymphoid tissue (MALT), either in the stomach or in a range of other organs such as salivary glands, the tissues around the eye or the thyroid. Many stomach MALT lymphomas are caused by infection with Helicobacter Pylori. This infection can also be associated with non-gastric MALT lymphomas, but the association has never been prospectively studied. Chlamydia Psittaci infection can cause MALT lymphoma in the orbit. The management of localised MZL outside the stomach is controversial and there have been no large prospective studies of any of the commonly-used treatments (radiotherapy, chemotherapy, surgery). No prospective studies have looked at the role of infection with Helicobacter pylori or the role of autoantibodies in these diseases. Radiotherapy is the best-characterised therapy in the literature and appears to have a high cure rate with low toxicity. The disease seems exquisitely radiosensitive. Management of localised MZL in Australia can be ad hoc and we have often seen patients who have undergone unnecessary mutilating surgery or ineffective chemotherapy. It has been reported that localised non-gastric MZL (stage I and II) can be cured with radiotherapy in a high percentage of patients (usually >70%) in retrospective studies from large centres such as Princess Margaret Hospital in Toronto. Workers from that centre will participate in this study. This study will: Prospectively report efficacy and toxicity for radiotherapy in MZL for the first time Definitively document Helicobacter Pylori status in all cases and Chlamydia status in orbital cases Provide a gold standard against which to compare new therapies This study won the award for the most highly supported study in its year at the TROG annual scientific meeting.Read moreRead less
Adult non-Hodgkin?s lymphoma (NHL) is one of the most rapidly increasing cancers of recent times. The rise has occurred worldwide in men and women of all ages. The reason for most of the rise is unknown. It has recently been proposed that part of the upsurge may be due to increases in sun exposure which have occurred during the same period. There is some indirect evidence to support this hypothesis. For example, the rate of occurrence of NHL is higher closer to the equator in Australia than it i ....Adult non-Hodgkin?s lymphoma (NHL) is one of the most rapidly increasing cancers of recent times. The rise has occurred worldwide in men and women of all ages. The reason for most of the rise is unknown. It has recently been proposed that part of the upsurge may be due to increases in sun exposure which have occurred during the same period. There is some indirect evidence to support this hypothesis. For example, the rate of occurrence of NHL is higher closer to the equator in Australia than it is in England and Wales, and NHL is diagnosed more frequently among British migrants to Victoria than it is in their homeland. The sunlight hypothesis will be tested by comparing the pattern of sun exposure in Tasmanians diagnosed with NHL during the years 1998-2001 and in a sample of Tasmanians without the disease. tasmania has been chosen because levels of ultraviolet (UV) radiation are low there in all but the summer months, when it approaches the levels of Brisbane, Sydney and Melbourne. There is therefore a greater difference in UV exposure between the most exposed and the least exposed in Tasmania, making it an ideal location to test the hypothesis. The link between NHL and a measure of melanin pigmentation in the skin will also be studied. The incidence of NHL is higher in lighter-skinned ethnic groups than it is in darker-skinned people living at the same latitude, but it is not known whether risk varies within Caucasian populations. A new measure of melanin in the skin, developed at the Menzies Centre for Population Health Research in Hobart, will better allow the effects of skin colour to be studied.Read moreRead less
The Role Of CD30 Overexpression In CD30-positive Non-Hodgkins Lymphomas
Funder
National Health and Medical Research Council
Funding Amount
$457,242.00
Summary
The CD30 molecule sits on the surface of normal blood cells, but in a type of cancer called Lymphoma, CD30 concentration is high. The level of expression of CD30 may determine if the cancer cell is killed by the normal defense mechanisms or is able to grow uncontrollably. We are studying the control elements of the CD30 gene to understand how control is lost when the cell becomes cancerous. This knowledge may lead to therapeutic strategies to control lymphoma.
EBV-specific T Cells As Therapy For Relapsed - Refractory EBV-positive Lymphomas
Funder
National Health and Medical Research Council
Funding Amount
$324,397.00
Summary
The presence of Epstein-Barr virus (EBV) withiin EBV-positive malignant lymphoma cases provides a potential target for adoptive immunotherapy. Previous studies have established that adoptive immunotherapy for certain subtypes of lymphoma with EBV-specific killer T cells can lead to remission of disease. The objective of this study is to examine whether a similar strategy but using an enhanced methodology can be applied for the treatment of a range of relapsed-refractory EBV-positive lymphomas.